Gossamer Bio, Inc.

Gossamer Bio is a clinical-stage biopharmaceutical company focused on developing and commercializing therapeutic treatments for pulmonary hypertension, including pulmonary arterial hypertension and pulmonary hypertension associated with interstitial lung disease. The company's primary investigational product candidate is seralutinib, an inhaled kinase inhibitor targeting PDGFR, CSF1R, and c-KIT pathways designed to address the underlying cellular overgrowth in lung blood vessels. Additionally, the company holds an option agreement to develop RT234, an investigational inhaled dry-powder formulation intended for on-demand symptom management. Its target population comprises patients suffering from progressive pulmonary vascular and fibrotic lung diseases.

The company operates globally through clinical research and development partnerships, including a collaboration agreement with Chiesi to co-develop seralutinib. Under this arrangement, the company leads global development and United States commercialization for pulmonary arterial hypertension and pulmonary hypertension associated with interstitial lung disease, while Chiesi maintains commercialization rights in other international territories. The provided text does not state the company's headquarters location.

Summary of the business section of Gossamer Bio's latest annual report, written by StockData.

“Actually paid” adjusts reported pay for changes in the value of equity awards. Shareholder return assumes $100 invested at the start of the measurement period, as disclosed by the company.

“As of March 10, 2026, we had 161 full-time employees and 1 part-time employee.”